SARS-CoV-2 cell entry and targeted antiviral development

查看全文 作　　者：Zinuo [1]Chen;Ruikun [1,2,3]Du;Jazmin M.Galvan [4]Achi;Lijun [4]Rong;Qinghua [1,2,3]Cui

机构地区：[1]College of Pharmacy,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;[2]Qingdao Academy of Chinese Medicinal Sciences,Shandong University of Traditional Chinese Medicine,Qingdao 266122,China;[3]Experimental Center,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;[4]Department of Microbiology and Immunology,College of Medicine,University of Illinois at Chicago,Chicago,IL 60612,USA

出　　处：《Acta Pharmaceutica Sinica B》索引2021年第11卷第12期,共10页

基　　金：supported by the Drug Innovation Major Project(No.2018ZX09711001,China);Shandong Provincial Natural Science Foundation,China(No.ZR2020MH383);Qingdao Social Benefiting Technology Program,China(No.21-1-4-rkjk15-nsh)。 摘　　要：Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the causative agent of the pandemic coronavirus disease 2019(COVID-19),which threatens human health and public safety.In the urgent campaign to develop anti-S ARS-CoV-2 therapies,the initial entry step is one of the most appealing targets.In this review,we summarize the current understanding of SARS-CoV-2 cell entry,and the development of targeted antiviral strategies.Moreover,we speculate upon future directions toward nextgeneration of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era. 关键词：SARS-CoV-2 Cell entry Spike protein Antiviral development Post-pandemic

相关文献

参考文献（136）
引证文献（7）
耦合文献（856）

参考文献(136)

引证文献(7)

耦合文献(856)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

SARS-CoV-2 cell entry and targeted antiviral development

参考文献(136)

引证文献(7)

耦合文献(856)

用户提示